SCHEMBL8499675

SCHEMBL8499675

COc1ccc(-c2nc3cc(OC)c(OC)cc3c(=O)[nH]2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 3/20 0.67
▸ PARP1 P09874 3/20 0.67
▸ TNKS2 Q9H2K2 3/20 0.67
▸ GUSB P08236 3/20 0.67
▸ NPC1 O15118 2/20 0.67
▸ RAB9A P51151 2/20 0.67
▸ CASP3 P42574 1/20 0.67
▸ SENP7 Q9BQF6 1/20 0.67
▸ SENP6 Q9GZR1 1/20 0.67
▸ ESR1 P03372 1/20 0.58
▸ KDM4E B2RXH2 3/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ MAPT P10636 2/20 0.58
▸ CYP1A1 P04798 2/20 0.52
▸ CYP1B1 Q16678 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ MEN1 O00255 1/20 0.52
▸ POLB P06746 1/20 0.52
▸ HPGD P15428 1/20 0.52
▸ KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6118802 0.88 TNKS (0.63) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL2722426 0.88 TNKS (0.64) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL874165 0.88 GUSB (0.68) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL259473 0.87 GUSB (0.67) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL20771302 0.86 HPGD (0.57) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL28463042 0.86 TNKS (0.74) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL17786340 0.81 TNKS (0.67) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL874164 0.80 GUSB (0.65) TNKSTNKS2GUSBNPC1RAB9A
SCHEMBL29593104 0.80 TNKS (1.00) TNKSPARP1TNKS2GUSBNPC1
SCHEMBL8502164 0.80 TNKS (1.00) TNKSPARP1TNKS2GUSBNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE36256-E ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) 1999-07-20 — — US disclosed
US-5795889-A INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1998-08-18 — — US disclosed
US-5656643-A QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-08-12 — — US disclosed
US-5646153-A INHIBITING ABNORMAL CELL PROLIFERATION RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1997-07-08 — — US disclosed
US-5480883-A Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1996-01-02 — — US disclosed
US-5409930-A Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives RHONE-POULENC RORER PHARMACEUTICALS INC. (US) 1995-04-25 — — US disclosed
EP-0584222-A4 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE POULENC RORER INT (US) 1994-07-06 — — EP disclosed
EP-0584222-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE. RHONE POULENC RORER INT (US) 1994-03-02 — — EP disclosed
WO-1992020642-A1 BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) 1992-11-26 — — WO disclosed
Send feedback